First American Bank Increases Position in Becton, Dickinson and Company (NYSE:BDX)

First American Bank raised its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 28.1% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,177 shares of the medical instruments supplier's stock after purchasing an additional 2,012 shares during the period. First American Bank's holdings in Becton, Dickinson and Company were worth $2,102,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the company. Bank of Jackson Hole Trust purchased a new position in Becton, Dickinson and Company during the 4th quarter worth $25,000. REAP Financial Group LLC lifted its stake in shares of Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after acquiring an additional 55 shares during the period. Picton Mahoney Asset Management lifted its stake in shares of Becton, Dickinson and Company by 61.4% in the 4th quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after acquiring an additional 54 shares during the period. Nexus Investment Management ULC acquired a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth $34,000. Finally, Hopwood Financial Services Inc. acquired a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth $39,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on BDX shares. Wells Fargo & Company cut shares of Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research note on Thursday, May 1st. The Goldman Sachs Group cut shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price objective for the company. in a research note on Friday, May 2nd. Piper Sandler cut shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and reduced their price objective for the company from $260.00 to $185.00 in a research note on Friday, May 2nd. Bank of America cut shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 target price for the company. in a research report on Thursday, May 1st. Finally, Raymond James Financial cut shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of "Hold" and an average target price of $219.22.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $168.58 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.64 and a current ratio of 1.13. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The firm has a 50 day moving average price of $179.58 and a 200 day moving average price of $211.27. The company has a market cap of $48.32 billion, a price-to-earnings ratio of 32.17, a PEG ratio of 1.27 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The company had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.35 billion. During the same period in the previous year, the firm earned $3.17 earnings per share. Becton, Dickinson and Company's revenue for the quarter was up 4.5% on a year-over-year basis. Sell-side analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 9th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, June 9th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.47%. Becton, Dickinson and Company's payout ratio is currently 79.39%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 479 shares of the stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the sale, the executive vice president now directly owns 4,887 shares of the company's stock, valued at approximately $964,107.36. This represents a 8.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP David Shan sold 1,166 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the sale, the executive vice president now directly owns 4,575 shares in the company, valued at $783,194.25. This trade represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.36% of the company's stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.